Open AccessEfficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
Author(s) -
Takashi Iizuka,
Kotaro Iemitsu,
Masahiro Takihata,
Masahiko Takai,
Shigeru Nakajima,
Nobuaki Minami,
Shinichi Umezawa,
Akira Kanamori,
Hiroshi Takeda,
Takehiro Kawata,
Shogo Ito,
Taisuke Kikuchi,
Hikaru Amemiya,
Mizuki Kaneshiro,
Atsuko Mokubo,
Tetsuo Takuma,
Hideo Machimura,
Keiji Tanaka,
Taro Asakura,
Akira Kubota,
Sachio Aoyagi,
Kazuhiko Hoshino,
Masashi Ishikawa,
Yoko Matsuzawa,
Mitsuo Obana,
Nobuo Sasai,
Hideaki Kaneshige,
Fuyuki Minagawa,
Tatsuya Saito,
Kazuaki Shinoda,
Masaaki Miyakawa,
Yasushi Tanaka,
Yasuo Terauchi,
Ikuro Matsuba
Publication year - 2016
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr2417w
Subject(s) - medicine , glycemic , interim analysis , type 2 diabetes , diabetes mellitus , blood pressure , confidence interval , hemoglobin , weight loss , type 2 diabetes mellitus , gastroenterology , insulin , surgery , randomized controlled trial , endocrinology , obesity
Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes mellitus (T2DM). We evaluated the efficacy and safety of ipragliflozin in the real-world clinical setting, with a focus on the changes of body composition up to 3 months of treatment.